Gemtuzumab ozogamicin is a drug-linked monoclonal antibody (an antibody-
drug conjugate) that was used to treat acute myelogenous leukemia from 2000 to
This page contains brief information about gemtuzumab ozogamicin and a
collection of links to more information about the use of this drug, research results,
Jun 21, 2010 ... Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the
drug Mylotarg (gemtuzumab ozogamicin) for patients with ...
Jul 19, 2015 ... Gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) is a
recombinant, humanized anti-CD33 monoclonal antibody (IgG4 κ ...
Information about the monoclonal antibody gemtuzumab (Mylotarg®), which is
mainly used as part of research trials to treat some types of acute myeloid ...
Mylotarg® (gemtuzumab ozogamicin for Injection) is a chemotherapy agent
composed of a recombinant humanized IgG4, kappa antibody conjugated with a
Nov 10, 2012 ... On May 17, 2000, the US Food and Drug Administration (FDA) granted
accelerated approval for the use of gemtuzumab ozogamicin (GO) in ...
Blood. 2013 Jun 13;121(24):4838-41. doi: 10.1182/blood-2013-03-490482. Epub
2013 Apr 16. Gemtuzumab ozogamicin in acute myeloid leukemia: a ...
Feb 15, 2013 ... In an era of personalized and targeted therapy, it seems illogical to withdraw
gemtuzumab, the only agent newly approved for the treatment of ...
Easy to read patient leaflet for gemtuzumab ozogamicin. Includes indications,
proper use, special instructions, precautions, and possible side effects.